Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS (NOVN)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Novartis : KHCC, Novartis Pharma AG sign cooperation agreement

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/04/2017 | 03:51pm CET

Oct. 04--AMMAN -- HRH Princess Ghida Talal, the chairperson of the King Hussein Cancer Foundation's board of trustees, on Tuesday signed a memorandum of understanding (MoU) with the CEO of Novartis Pharma AG, Bruno Strigini, the Jordanian News Agency, Petra, reported.

The memorandum aims at enhancing cooperation between the two corporations in scientific research."Research is considered a vital and integrated part at [KHCC] to improve the diagnostic and treatment process of cancer patients, which is in-line with the centre's efforts that is aimed towards saving our patients," Princess Ghida said.

The memorandum was signed in the presence of Asem Mansour, director general of KHCC and Hekmat Abdul Razzaq, deputy director general of KHCC.

___

(c)2017 the Jordan Times (Amman, Jordan)

Visit the Jordan Times (Amman, Jordan) at www.jordantimes.com

Distributed by Tribune Content Agency, LLC.

© Tribune Content Agency, source Regional News

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
12/14 NOVARTIS : initiates study evaluating impact of higher dosing of Cosentyx® in pa..
12/14 NOVARTIS : New Angioedema Data Have Been Reported by Investigators at Novartis (..
12/14 STUDY DATA FROM NOVARTIS UPDATE UNDE : A Continuous Manufacturing Enabled Sequen..
12/14 NOVARTIS : Sandoz announces new Phase I data showing proposed biosimilar pegfilg..
12/14 NOVARTIS : drug crizanlizumab shown to prolong time to patients' first sickle ce..
12/14 ONCY VENT : Result of Oncology Ventures Drug Response Prediction for TKI drug fr..
12/13 Aduro discontinues development of CRS-207
12/12 NOVARTIS : initiates study evaluating impact of higher dosing of Cosentyx in pat..
12/12 NOVARTIS : Sandoz announces new Phase I data showing proposed biosimilar pegfilg..
12/11 NOVARTIS : drug crizanlizumab shown to prolong time to patients' first sickle ce..
More news
News from SeekingAlpha
12/14 Did ASH Just Change The Juno Best In Class Thesis?
12/14 More Positives For Roche, The Core Biotech For The Long Run
12/13 CONATUS : Likely To Dash Ahead Of NASH Data
12/12 Novartis (NVS) Highlights From ASH And SABCS - Slideshow
12/11 Buy Celgene And Regeneron On The Dips As Insiders Are Buying
Financials ($)
Sales 2017 49 174 M
EBIT 2017 11 962 M
Net income 2017 7 465 M
Debt 2017 17 812 M
Yield 2017 3,34%
P/E ratio 2017 24,71
P/E ratio 2018 21,53
EV / Sales 2017 4,86x
EV / Sales 2018 4,66x
Capitalization 221 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Average target price 87,4 $
Spread / Average Target 2,7%
EPS Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS13.16%221 304
JOHNSON & JOHNSON21.53%383 877
PFIZER10.04%218 400
ROCHE HOLDING LTD.3.40%210 833
MERCK AND COMPANY-6.96%155 214
AMGEN19.97%128 762